News Article | November 4, 2016
OXEN HILL, Md.—R&D Magazine has announced the Winners of the 54th annual R&D 100 Awards, an international competition that recognizes the 100 most technologically significant products introduced into the marketplace over the past year, at the R&D 100 Awards Ceremony held last night at the Gaylord National Resort & Convention Center. The R&D 100 Awards recognize excellence across a wide range of industries, including telecommunications, optics, high-energy physics, materials science, chemistry, and biotechnology. R&D 100 Award recipients include established Fortune 500 companies and federally funded research institutions, as well as academic and government labs. The awards not only recognize the efforts of the development team and partners, they provide a mark of excellence known to industry, government and consumers. The full list of 2016 R&D 100 Award Winners is available here: www.rd100conference.com/awards/winners-finalists/year/2016/ The 2016 R&D 100 Awards Banquet took place on Nov. 3, 2016 at the Gaylord National Harbor & Resort in Oxon Hill, Maryland, where R&D Magazine also presented the R&D 100 Conference, which will conclude today. Last night at the annual black-tie awards ceremony, the leaders of science and technology industries were honored for their innovative, high-tech products and processes. This year, the R&D 100 Finalists were also recognized for their high achievements within the five categories described at the ceremony, including Analytical/Test, IT/Electrical, Mechanical/Materials, Processing/Prototyping, and Software/Services. Along with honoring the 100 best technologies of the year, R&D Magazine also presented Scientist of the Year and Innovator of the Year awards. The 2016 Scientist of the Year is Dharmendra S. Modha, Ph.D., who is an IBM Fellow and IBM Chief Scientist for Brain-inspired Computing. He is a Cognitive Computing pioneer who envisioned and now leads a highly successful effort to develop brain-inspired computers. The project has received more than $65 million in research funding from DARPA, the U.S. Department of Defense, the U.S. Department of Energy, and industry. This ground-breaking project is multi-disciplinary, multi-institutional and multi-national, and has a worldwide scientific impact. Mark C. O’Riley, Esq., from Technology Policy, IBM Government and Regulatory Affairs accepted the award on his behalf. The 2016 Innovator of the Year is Anthony Atala, MD, Director of the Wake Forest Institute for Regenerative Medicine and the W. Boyce Professor and Chair of Urology at Wake Forest University, who has done pioneering work in 3D bioprinting. Dr. Atala spoke to the spell-bound audience about his revolutionary work in regenerative medicine. The R&D 100 Awards Ceremony also unveiled the R&D 100 Special Recognition Awards, with Gold, Silver, Bronze and Merit Awards announced during the ceremony. These included the Green Tech Special Recognition Award, Corporate Social Responsibility Special Recognition Award, Market Disruptor Services Special Recognition Award, and Market Disruptor Product Special Recognition Award. You can see the full list here: www.rd100conference.com/awards/special-recognition-finalists/year/2016/ The R&D Editor’s Choice Award topped off the gala event. This year also marked the second R&D 100 Awards Conference, which took place November 2 to 4. This science and technology conference offered attendees in-depth presentations by industry experts in General Sessions, Keynotes and three educational tracks to inspire conversations and offer best practices, insights and solutions. Entries for the 2016 R&D 100 Awards are now open. Please go to www.bitly.com/2017-rd100 for more information. Since its founding in 1959 as Industrial Research, R&D Magazine (www.rdmag.com) has served research scientists, engineers, and technical staff at laboratories around the world, providing timely, informative news and useful technical articles that broaden readers’ knowledge of the research and development industry and improve the quality of their work. R&D Magazine is a publication of the Advantage Business Media Science Group, with sister brands including Laboratory Equipment, Bioscience Technology, Drug Discovery & Development, Laboratory Design, Scientific Computing, and Controlled Environments.
News Article | December 14, 2016
For the energy transition to be successful, it will also be important to secure heat supply of the housing stock by sustainable technologies. About half of the apartments in Germany is located in apartment buildings. However, backfitting with modern building shells or heat pumps lags behind. The cooperation project "LowEx-Bestand" coordinated by KIT and Fraunhofer ISE is aimed at developing commercially viable concepts and demonstrating their operation quality. It is funded with about EUR 5.3 million by the Federal Ministry for Economic Affairs and Energy. "The two most important keys to reaching a nearly climate-neutral housing stock are thermal insulation and low-carbon dioxide heating technology," emphasizes project head Professor Hans-Martin Henning, Holder of the Chair for Technical Energy Systems of Karlsruhe Institute of Technology (KIT) and Coordinator of the Business Area of Building Energy Technology of the Fraunhofer Institute for Solar Energy Systems ISE, Freiburg. "At the same time, the measures have to be economically efficient." The cooperation project "LowEx-Bestand" focuses on the further development and demonstration of measures to reduce energy consumption of existing apartment houses and is aimed at developing new, viable solutions in close cooperation with industry partners. As regards the energy saving potential, past activities mostly focused on technology rather than on building-specific framework conditions and compliance of new technology with the building in need of refurbishment. This is where the project "LowEx-Bestand" starts. So far, complexity of construction and refurbishment processes has prevented wide implementation of new solutions. The cooperation project is now aimed at finding user-compatible refurbishment approaches that improve building quality and enhance and facilitate workflows. Heat pumps are already widely used to supply many single- and two-family houses with heat with low carbon dioxide emissions. However, heat pumps are hardly applied in apartment houses, although they are among the heating technologies that contribute most to a significant reduction of the emission of climate gases in the supply of room heat and hot water, in particular when power from renewable sources is used. Use of heat pumps in apartment houses, however, is associated with several challenges that will be addressed under "LowEx-Bestand," in particular in the area of hot water production, legionella protection, and use of alternative heat sources, i.e. geothermal heat or heat from outside air. In this connection, gas-driven heat pumps that are driven by natural gas instead of electricity are a promising alternative. Compared to pure gas boilers, they are associated with reduced specific carbon dioxide emissions. Gas-driven heat pumps require a smaller heat source than electric heat pumps, which is a big advantage in buildings in urban regions. These buildings mostly are connected to the gas grid. For this reason, gas-driven heat pumps will be evaluated as another technical option for existing apartment houses. In the area of thermal insulation, "LowEx-Bestand" will focus on refurbishment solutions that affect the inhabitants to the smallest possible extent. For this, pre-fabricated facade elements will be developed and used. They do not only contain the thermal insulation, but also heating and ventilation components. As a result, construction work inside the apartments is reduced. At the same time, a high degree of pre-fabrication promises to increase economic efficiency of refurbishment. Under the "LowEx-Bestand" cooperation project, research institutes, technology companies, and the housing sector cooperate closely in the areas of thermal insulation and heat pump. New building energy concepts are developed, implemented, demonstrated, and evaluated with the help of measurements. The project is aimed at further developing new concepts in the area of energy-oriented refurbishment of the building shell and use of heat pumps for existing apartment houses, at enhancing their economic efficiency, securing the operation quality, and contributing to an accelerated introduction and commercialization on the market. In this way, the project will make a significant contribution to reaching the climate policy objectives envisaged in Germany in the area of heat supply of buildings. The cooperation project has a budget of EUR 6.4 million, of which EUR 5.3 million are funded by the Federal Ministry for Economic Affairs and Energy (BMWi). The cooperation project is headed by the Professor for Technical Energy Systems of the KIT Department of Mechanical Engineering, Professor Hans-Martin Henning. Other research partners are the KIT Institute for Industrial Production (IIP) of the KIT Department of Economics (Professor Wolf Fichtner), the Building Science Group (fbta) of the KIT Department of Architecture (Professor Andreas Wagner), and several groups of the Fraunhofer Institute for Solar Energy Systems (ISE) in Freiburg. Temperature conditioning of rooms on comfortable level cannot only be achieved by locally high temperatures reached by burning fossil fuels. Sustainable systems rather work with low temperature differences between the heating medium and room temperature. In this way, also regenerative energy sources, such as ambient heat in combination with heat pumps, can be used much better. The term LowEx (Low Exergy) stands for systems needing a small amount of "valuable" energy, so-called exergy. Exergy means the usable part of total energy of a system that can perform work and does not exist in the form of diffuse heat. The "LowEx-Bestand" cooperation project is part of a large-scale project alliance covering several technology projects for the further development of systems and devices in cooperation with manufacturers. The cooperation project of KIT and Fraunhofer ISE also covers several demonstration projects in the area of thermal insulation and the use of heat pumps. These projects are planned to be carried out in existing apartment houses in cooperation with the housing sector. They include measurements and their evaluations as well as processing of the results for users and the interested public. The Fraunhofer Institute for Solar Energy Systems ISE was established in Freiburg im Breisgau in 1981. With a staff of about 1100, Fraunhofer ISE is the largest solar energy research institute in Europe. It develops technological fundamentals for efficient and environmentally friendly energy supply in industrialized as well as in threshold and developing countries. In the areas of energy production, energy efficiency, energy distribution, and energy storage, it contributes to a wide application of new technologies. For further information, please contact: Marion Hopf, Fraunhofer ISE Press and Public Relations, Phone: +49 761 4588-5448 E-Mail: firstname.lastname@example.org More about building energy technology of Fraunhofer ISE: https:/ More about the KIT Energy Center: http://www. For further information, please contact: Kosta Schinarakis, KIT Science Scout, Phone: +49 721 608 41956, Fax: +49 721 608 43658, Email: email@example.com Karlsruhe Institute of Technology (KIT) pools its three core tasks of research, higher education, and innovation in a mission. With about 9,300 employees and 25,000 students, KIT is one of the big institutions of research and higher education in natural sciences and engineering in Europe. KIT - the Research University in the Helmholtz Association Since 2010, the KIT has been certified as a family-friendly university. This press release is available on the internet at http://www. .
News Article | October 31, 2016
Peter K. Dorhout, Vice President for Research at Kansas State University, has been elected the 2017 American Chemical Society president-elect by members of ACS. Dorhout will serve as president of the society in 2018 and immediate past-president in 2019; he will also serve on the board of directors during that time. With 10,407 votes, Dorhout won the race against Thomas R. Gilbert, acting chair of the department of chemistry and chemical biology at Northeastern University, who received 7,319 votes. The society, which publishes C&EN, also elected or reelected four other board directors. “I’m humbled and grateful for the support of the membership,” Dorhout says. “They have given me an opportunity and a tremendous responsibility to help lead this organization.” “I’ve had the opportunity to visit with a lot of members over the course of this year at national meetings, at the regional meetings, and I’ve learned a lot about what people are concerned about. Young folks are concerned about finding that first job, and when I have polled the individuals, they often don’t realize the resources that ACS has. “I would like to have regular virtual town hall meetings as president elect to just hear from the membership, what are the things they’re most concerned about and what ideas do they have to help us out,” Dorhout continues. “I think there are a lot of talented members that have given a lot of thought to our position in the world, and I want to open the doors to communicate with them.” In other election news, Christina C. Bodurow, senior director of external sourcing in the medicines development unit at Eli Lilly & Co. in Indianapolis, was elected director of District II, defeating incumbent George M. Bodner, Arthur E. Kelly Distinguished Professor of Chemistry at Purdue University. And Rigoberto Hernandez, professor of chemistry at Johns Hopkins University, was re-elected director of District IV, edging out Larry K. Krannich, executive director of the Alabama Academy of Science in Birmingham. Kathleen M. Schulz, president of Business Results in Albuquerque, and Dorothy J. Phillips, who is retired from Waters Corp., were elected director-at-large. They won over Joseph A. Heppert, associate vice chancellor for research at the University of Kansas, and Kristin M. Omberg, group leader in the Chemical & Biological Signature Science Group at Pacific Northwest National Laboratory. Some 17,726 valid votes were cast for President-Elect. Voter participation for president-elect was more than 11.62% of all eligible voters. Additional information about the winners can be found in the candidates’ statements.
News Article | December 12, 2016
The Future Science Group (FSG) published journal, Melanoma Management, has released a special issue highlighting the advancements made in viral immunotherapies and vaccines in the melanoma field. Over the last few years, melanoma has been at the center of some of the latest advances in cancer immunotherapy, with monoclonal antibodies such as anti-CTLA-4 and anti-PD-1 currently FDA- approved for use in late stage disease. Moreover, focus is now being given to potential melanoma vaccines, comprised of tumor-associated antigens and intralesional viral therapies. Highlights from the special issue include articles discussing how dendritic cell vaccines have developed since their inception to their use today in various clinical trials, as well as a comment on ongoing clinical trials for a variety of cancer vaccines. The issue further appraises various vaccine targets and intralesional therapies currently being developed for melanoma, as well as those already used in the clinic today, such as the oncolytic immunotherapy talimogene laherparepvec (T-VEC). Guest Editor for the special issue, Robert O Dillman (AiVita Biomedical, CA, USA) stated: "This special focus issue of Melanoma Management highlights the latest advancements in melanoma immunotherapy with respect to cancer vaccines and viral-based therapies, with a range of articles discussing the developments in various vaccine candidates for melanoma as well as expert opinions and experiences with such vaccines both in clinical trials and in standard practice." "The use of immunotherapies in melanoma has provided the field with exciting results and opened further avenues for treating the malignancy," commented commissioning editor for Melanoma Management Sebastian Dennis-Beron. "It has been a pleasure to work with a group of renowned experts on the fore-front of this field to develop this special issue on these immunotherapies, which could revolutionize melanoma treatment in the future". Dillman's foreword as guest editor is free to read, here: http://www. Melanoma Management launched in 2014 and is currently a quarterly forum for reviews, opinion, analysis and original research from international experts. The aim of our journal is to provide concise, up-to-date and clinically relevant content for the melanoma community through publication in both print and online formats and through our new partnership with Oncology Central (http://www. ). Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.
News Article | December 1, 2016
Extended R&D Collaboration of Oral Diabetes Drugs Promising to Meet Unmet Needs Complements the Group's R&D Capabilities and Diabetes Treatment Portfolio HONG KONG, CHINA--(Marketwired - Dec 1, 2016) - Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group"; HKEx code: 690) has today announced that it has signed a multiple drug co-development deal with Beijing Sun-Novo Pharmaceutical Research Co., Ltd. ("Beijing Sun-Novo"), a China-based company engaged in research and development (R&D), manufacturing and commercialization of pharmaceutical products, to extend Uni-Bio's current R&D capabilities in small molecule drug development. This cooperation includes co-development of various oral anti-diabetes drugs ("OAD") to build a comprehensive diabetes treatment portfolio for the Group, which would represent an all-encompassing strategy in satisfying the unmet needs in treatment of this increasingly prevalent disease. The first co-development project of the two companies is to develop high quality Acarbose tablets for treatment of Type 2 diabetes, an emerging and increasingly important diabetes treatment in China. Under this collaboration, Beijing Sun-Novo is to be responsible for completing the chemistry, manufacturing and control (CMC) processes and the bioequivalence study of Acarbose, as well as transferring the production technology to Uni-Bio Science's subsidiary. On the other hand, Uni-Bio Science is to apply for drug licenses from the China Food and Drug Administration with support from Beijing Sun-Novo and commercialize the product once it is approved. The project is targeted to start in 2017 and launch sales in the market around 2020 to 2021. Mr. Kingsley Leung, Executive Director of Uni-Bio Science, said, "Our cooperation with Beijing Sun-Novo is an exciting opportunity to realize our goal quickly of becoming an industry-leading expert in diabetes management. With the incidence of diabetes reaching epidemic levels in China and across the world, there is a need for a wider range of treatment options to better manage this long-term chronic condition. This multiple co-development deal can strengthen our R&D capabilities and enhance our current positioning of our portfolio to meet the increasing market demand. We are planning to collaborate on various OAD to satisfy unmet medical needs, and Acarbose is another important component of a comprehensive diabetes product strategy targeting 1st-to-4th line of treatment within the Chinese treatment guideline. As this collaboration progresses, we hope to develop two or more OADs that can further complement our existing diabetes portfolio of Mitiglinide and rExtendin-4 (Uni-E4)." Mr. Li Qian, Chairman of Beijing Sun-Novo, said, "Uni-Bio Science and Beijing Sun-Novo, as strategic partners, will strive to introduce medical innovations that improve treatment efficacy and the quality of living of diabetics in China and also to cooperate in depth on diabetes, dermatological and ophthalmological products in the future through upholding the principles of working as one and aiming for win-win outcomes. With a seasoned R&D team, the company has developed a sound quality testing and control system, forged a complete industry chain integrating production operations and aligned R&D to ensure efficient cooperation in compliance with all rules and regulations. We believe the complementary partnership will help enhance the value of Beijing Sun-Novo and boost our strengths in innovation and R&D while injecting new impetus into Uni-Bio Science, and together we may welcome a new era for pharmaceuticals as we both benefit. We will strive to build a new platform for furthering cooperation, development and exchanges in areas including resources allocation, business integration, workflow and service coverage, thereby generating synergies and improving innovation capabilities, for the goal of achieving strategic breakthroughs in development. " Acarbose is an oral anti-diabetic drug which belongs to the Alpha-Glucosidase Inhibitors ("AGI") class. It is used to treat Type 2 diabetes and is reimbursed under the National Reimbursement Drug List ("NRDL"). In terms of diabetes treatment, AGI is important for the early stage of diabetes. It targets patients with pre-diabetes condition who need to be treated early, and those with post prandial hyperglycemia under control. According to IMS China Data, AGI is uniquely positioned within China's diabetes guidelines, maintaining around 18% of China's anti-diabetes drug market in 2012 to 2015, which is especially effective for Asian patients with a high-carbohydrate diet content. Acarbose has the largest market share at 87.8% in China's AGI market in 2015, which represents a market size of RMB3.4 billion. Meanwhile, the domestic sales revenue of Acarbose increased at a compound annual growth rate of 10.3% from 2012 to 2015, which clearly shows the enormous potential and promising growth opportunities of the drug in the market. About Uni-Bio Science Group Limited (SEHK: 0690) Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology. About Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is a national high-tech company with international ISO9001:2008 quality management certification. With a 1,200 sq.m. laboratory and an R&D team comprising more than 70 professionals, the Company is well-positioned as a high-tech enterprise focusing on the R&D of pharmaceutical technologies and Active Pharmaceutical Ingredient ("API") intermediate trading. It strives to conduct innovative research and provide contract services in relation to pharmaceutical technologies riding on its advantages in R&D for new medicines and a commercialization model. The Company also has its own professional team and standardized laboratory for conducting R&D of new medicines, industrial production and API trading. Its core businesses cover R&D for chemical formulas of medicines, transfer of expertise and cooperation, API intermediate production and trading, clinical research services and import registration.
News Article | November 11, 2016
ROCKAWAY, N.J., Nov. 10, 2016: Science and technology industry leaders gathered to watch the presentation of the 2016 Scientist of the Year at the 54th annual R&D 100 Awards Ceremony in Washington, D.C., on Nov. 3, 2016. This year marks the 51st annual Scientist of the Year Award, which recognizes career accomplishments in scientific research and technology spanning nearly all disciplines from physics to medicine to chemistry. Along with honoring the 100 best technologies of the past year at this annual R&D 100 Awards event, R&D Magazine has named Dharmendra Modha, Ph.D., IBM fellow and IBM chief scientist for brain-inspired computing and the creator of the most advanced brain-inspired computer, as the 2016 Scientist of the Year. His accomplishments and remarkable journey were profiled in the October 2016 issue of R&D Magazine. Mark C. O’Riley, Esq., Technology Policy, IBM Government and Regulatory Affairs, accepted on behalf of Modha, who also spoke to the R&D 100 Awards audience via video. “As a cognitive computing pioneer, it is our great honor to recognize the ground-breaking efforts of Dr. Modha as he brings new insights into the power of the brain—and continues to refine and accelerate our knowledge of this new landscape, which has worldwide scientific impact,” said Bea Riemschneider, editorial director of the Advantage Business Media Science Group, the parent organization of the R&D 100 Awards and R&D Magazine. Modha envisioned and now leads a highly successful effort to develop brain-inspired computers. Delivering on a promise he made six years ago, Modha and his team have revolutionized the computing industry with the introduction of TrueNorth—a chip with a brain-inspired computer architecture powered by an unprecedented 1 million neurons and 256 million synapses. Traditional computers focus on language and analytical thinking, but neurosynaptic chips are built to address senses and pattern recognition. In true pioneer fashion, the chips turned more than 70 years of computer architecture on its head, redefining what is now possible in the field of brain-inspired computers in terms of size, architecture, efficiency, scalability and chip design techniques. This ground-breaking project is multi-disciplinary, multi-institutional and multi-national. The 2016 Scientist of the Year is also the author of more than 60 papers and inventor of more than 100 patent disclosures. In 2013 and 2014, Modha was named the Best of IBM and he has made significant contributions to IBM businesses via innovations in caching algorithms for storage controllers, clustering algorithms for services and coding theory for disk drives. He holds a B.Tech. in Computer Science and Engineering from IIT Bombay and a Ph.D. in Electrical and Computer Engineering from the University of California at San Diego. The R&D 100 Awards Committee and R&D Magazine unveiled the 2016 R&D 100 Awards at the annual black-tie dinner, which honors the 100 most innovative technologies, products and services of the past year. A detailed list of the 2016 R&D 100 Awards can be found here. In addition to the awards gala, this year’s event also included the second annual R&D 100 Conference, which featured an impressive roster of educational sessions and networking opportunities. The conference’s theme was “R&D Strategy, Innovation and Leadership.” For more information on the R&D 100 Awards program for 2017, click here. Since 1963, the R&D 100 Awards program has identified revolutionary technologies newly introduced to the market. The R&D 100 Awards identifies and celebrates the top technology products of the year. Past winners have included sophisticated testing equipment, innovative new materials, chemistry breakthroughs, biomedical products, consumer items, and technologies spanning industry, academia and government-sponsored research.
News Article | September 8, 2016
The R&D 100 Awards Committee and R&D Magazine announced the 2016 R&D 100 Special Recognition Awards Finalists, a new honor instituted in 2015 to recognize those products that shine in specific areas such as green technology and corporate social responsibility. They will be announced for the second year at the 54th annual R&D 100 Awards gala event, the annual black-tie awards dinner, being held on Nov. 3, 2016 at the Gaylord National Resort & Convention Center in Oxon Hill, Maryland (Washington, D.C.). The R&D 100 Awards Finalists for Special Recognition were selected by an independent panel of judges and represent contributions by leading R&D companies and national laboratories that entered their products to be recognized for specific aspects of their newest innovations. “These Special Recognition Awards are a new way for R&D Magazine to highlight companies that strive to create products and technologies that answer specific needs for the R&D community, and it is our pleasure to recognize these important efforts to move innovation forward,“ said Bea Riemschneider, editorial director, ABM Science Group, R&D Magazine. “By becoming an R&D 100 Special Recognition Awards Finalist, these companies are being recognized for their excellent contributions to advancing science and technology in a notable space—and they are joining a very exclusive community.” For the second year, the R&D 100 Awards Committee will honor excellence in these four special recognition categories – Market Disruptor Services, Market Disruptor Products, Corporate Social Responsibility, and Green Tech. The Special Recognition Market Disruptor Services Award is designed to highlight any service from any category as one that forever changed the R&D industry or a particular vertical within the industry. The Special Recognition Market Disruptor Products Award highlights any product from any category as one that has changed the game in any industry in the last year. The Special Recognition Social Responsibility Award honors organizational efforts to be a greater corporate member of society from a local to global level. Finally, the Special Recognition Green Tech Award recognizes those innovations that help make our environment greener and our goal towards energy reduction closer from an engineering and societal perspective. A detailed list of the 2016 R&D 100 Special Recognition Awards Finalists can be found here. In addition to the awards gala, this year’s event has been expanded to include the R&D 100 Conference, Nov. 2-4, featuring an impressive line-up of educational sessions and networking opportunities. The conference will open with a Keynote by Rosemarie Truman, founder and CEO of The Center for Advancing Innovation, who will speak on “Valuable Federal Inventions: Moon Shot Unicorns Waiting to Be Tapped!” The Keynote for the second day will be presented by Stephen Shapiro, Hall of Fame speaker and best-selling author, who will present “Innovate the Way You Innovate!” For the full R&D 100 Conference agenda click here. Since 1963, the R&D 100 Awards program has identified revolutionary technologies newly introduced to the market. Widely recognized as the “Oscars of Invention,” the R&D 100 Awards identify and celebrate the top technology products of the year. Past winners have included sophisticated testing equipment, innovative new materials, chemistry breakthroughs, biomedical products, consumer items, and high-energy physics spanning industry, academia, and government-sponsored research. R&D Magazine instituted the R&D 100 Special Recognition Awards in 2015 to highlight and honor specific aspects of new products, technologies and services.
News Article | April 23, 2016
« IMO agrees mandatory system for collecting ships’ fuel consumption data | Main | Utah Transits Authority adding 5 battery-electric New Flyer buses to fleet » Ford recycles as much as 20 million pounds (10,000 short tons, 9 million kg) of aluminum stamping scrap per month using the closed-loop system at Dearborn Truck Plant, which builds F-150. That amount is the equivalent of more than 30,000 F-150 bodies in the largest configuration—a SuperCrew body including doors, plus hood, tailgate and 6.5-foot cargo box. Weight savings from aluminum alloy helps F-150 reduce its lifetime emissions compared to the previous steel-body version. Between 30% and 40% of a typical aluminum coil is turned into scrap in the stamping process. This is recycled into new metal for the truck using the closed-loop system. Recycled aluminum avoids 95% of the greenhouse gas emissions associated with primary aluminum production. It uses significantly less energy and water—another reason Ford F-150 leads the full-size truck pack in terms of lifetime carbon footprint, according to Automotive Science Group. When equipped with the available 2.7-liter EcoBoost with standard Auto Start-Stop technology, F-150 4x2 has best-in-class EPA-estimated gasoline fuel economy ratings of 19 mpg city, 26 mpg highway and 22 mpg combined (actual mileage will vary).
News Article | November 14, 2016
Joins Forces with LUQA in Co-promoting Drugs and Medical Devices for Treatment of Dermatological Disorders in Mainland China HONG KONG, CHINA--(Marketwired - Nov 14, 2016) - Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group") ( : 0690) has today announced that it has established a strategic partnership with Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd. ("LUQA"), a China-focused specialty pharmaceutical company, to conduct co-promotion or/ and co-marketing of dermatology drugs in Mainland China, enabling the Group to immediately expand its income stream and generate cash flow. Under the terms of the strategic alliance agreement, products for co-promotion or/ and co-marketing cover drugs or medical devices for the treatment of dermatological disorders, including but not limited to Uni-Bio Science's and LUQA's current and future innovations in the dermatology field. More specifically, under the terms of the three-year promotion agreement with an option to renew for two additional years, Uni-Bio Science will co-promote selected products in hospitals or qualified institutions, drug stores and retail channels in certain territories. Uni-Bio Science will additionally support LUQA with market access in the territories, including provincial and national reimbursement expansion of products under collaboration. Mr. Kingsley Leung, Executive Director of Uni-Bio Science said, "Promptly following our strategic alliance with China Resources Zizhu forged in June, I am very excited to announce this strategic partnership with LUQA, which not only reinforces our partnership model, but also enables us to accelerate the penetration of drugs or medical devices of our current product lines for dermatological treatment - a major therapeutic area of the Group - in Mainland China. LUQA has a very interesting product portfolio in dermatology, especially in the aesthetics space. A number of these products can be co-promoted with our GeneTime® to provide a comprehensive solution for our patients in terms of wound and scar management. Leveraging our success with GeneTime® in China, we are confident of effectively expanding the footprint of LUQA's products in the market. In this way we can create a win-win situation for both parties and cement our leadership position in the dermatology market." Mr. Robert Braithwaite, Chief Executive Officer of LUQA said, "This collaboration enables us to work together to bring forward innovative medical solutions demonstrated to improve outcomes and quality of life to patients in China. Uni-Bio Science has demonstrated over the years the strength of their commercial teams in accessing and educating physicians. We believe this co-promotion agreement will drive value for LUQA and reinforce our market leadership position in innovative skin solutions for medical and aesthetic dermatology. This cooperation is synergistic with our group's existing commercial efforts for our products in the hospital market and will enable us to further strengthen our commercial capabilities as we prepare to market additional medical and aesthetic products." Apart from this latest cooperation forged with LUQA, in June 2016, the Group had signed a strategic alliance agreement with China Resources Zizhu Pharmaceutical Co., Limited to distribute and promote GeneSoft® in Mainland China for a minimum of five years. In addition, the Group has partnered heavily in the past two years with both foreign and domestic companies to bring a number of important therapies in the ophthalmology and diabetes space to patients. Going forward, the Group is keeping a close eye on the opportunities of in-licensing or acquiring products or technologies that complement its pipeline products, including but not limited to Uni-E4 for the treatment of Type-2 diabetes. With a clear development roadmap, Uni-Bio is well on the way to continue "Leading Genuine Innovation" and maintain rapid growth in the market. Image Mr. Kingsley Leung, Executive Director of Uni-Bio Science Group Limited (left) and Mr. Robert Braithwaite, Chief Executive Officer of Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd. (right) sign an agreement to establish a strategic partnership of the two companies. http://release.media-outreach.com/i/Download/6113 About Uni-Bio Science Group Limited ( : 0690) Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology. About Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd. Luqa Pharmaceuticals Trading (Shanghai) Co., Ltd. is a China-focused company. It acquires, develops and commercialises innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. Luqa aims to become a leader in specialty care segments in China, Hong Kong and Macau.
News Article | February 27, 2017
Uni-Bio Science Group Limited ("Uni-Bio Science" or the "Group;" HKEx code: 690) has announced that its product Mitiglinide is now to be officially reimbursed under the National Reimbursement Drug List ("NRDL") published by Ministry of Human Resources and Social Security today. Meanwhile, GeneTime already included on the NRDL, lifted from the restricted use in only occupational injury claims. Therefore both drugs are now accessible to all patients under general medical claims which should accelerate the market penetration of Uni-Bio Science's drugs while expediting the Group's business growth. The lifting of restrictions limiting use only for occupational injury claims is expected to be a great driver of expanding GeneTime use in new departments where wounds are not caused by industrial or work-related accidents. From surgical incisions to chronic wounds, GeneTime can be applied to a wide range of medical conditions, for example skin burns, plastic surgery and even incisions in gynecologic and orthopedics surgeries. Recent study reported that caesarean section delivery rate in China was as high as over 34%, or an average of 11 babies delivered by caesarean sections per minute. Upon the ending of China's one-child policy and increasing occurrence of high risk pregnancies, the number of caesarean sections carried out in China is expected to rise rapidly. With the restriction lifted, GeneTime is on track to capture the growing market potential on a heightened level. Besides the lift, GeneTime is also the only drug recognized as a new EGF entry (i.e. rhEGF I) in the latest NRDL, meaning that its uniqueness differentiates itself from the rest of the EGF products in the market. This listing endorses GeneTime's positioning as an advanced treatment choice for doctors and other medical professionals. Mr. Kingsley Leung, Chairman and Executive Director of Uni-Bio Science said, "I am very excited to announce the successful designation of these two products on the NRDL. The Group hopes to unlock the extensive growth potential of Mitiglinide and raise its revenue contribution in the future. Besides, lifting GeneTime's reimbursement restriction is a very pleasant surprise. The prospects are exciting, and the change will increase the quality-of-life in a large number of patients undergoing various surgeries. Many people do not know that poor wound management can cause posttraumatic stress disorder, such as anxiety and insomnia. For example, this is normally seen in women who have undergone cesarean section. Many women feel unattractive in front of their husband, embarrassed and humiliated in public. With better education of wound management, and increased use of certain wound and scar treatments (such as GeneTime), we hope to help these patients live a happier life. With the change in NRDL status, this is a very positive step forward. In addition, our co-promotion partnership on various dermatology and aesthetics products with LUQA Pharmaceuticals last year would also help provide more treatment options for patients." Mitiglinide is a new, potentially best-in-class oral anti-diabetic agent which belongs to the glinides class of blood glucose-lowering compounds. Market size of glinides class drugs in China was over RMB1.2 billion and its demand for Mitiglinide has showed a strong annual growth rate of over 50%, as of 2015. Currently there are over 90 million patients with Type 2 diabetes in China and the number is expected to rise rapidly in the coming decade. Mitiglinide supplements Uni-Bio's current endocrinology pipeline and the commercial expertise of Mitiglinide will benefit the Group before the launch of its proprietary products Uni-E4 and Uni-PTH. GeneTime is the only rhEGF (Recombinant human Epidermal Growth Factor) spray available in China for accelerating wound healing and reducing scar formation. GeneTime enhances Uni-Bio Science's treatment portfolio for patients in dermatology specifically in terms of wound and scar management. About Uni-Bio Science Group Limited Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two cGMP compliant manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology. Contact: